New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography

被引:24
作者
de Santana, FJM [1 ]
Cesarino, EJ [1 ]
Bonato, PS [1 ]
机构
[1] Univ Sao Paulo, Fac Ciencias Farmaceut, BR-14040903 Ribeirao Preto, SP, Brazil
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 809卷 / 02期
基金
巴西圣保罗研究基金会;
关键词
enantiomer separation; mirtazapine; antidepressant; chiral stationary phase;
D O I
10.1016/j.jchromb.2004.07.012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, rapid and sensitive high-performance liquid chromatography (HPLC) method was developed for the enantioselective analysis of the new antidepressant drug mirtazapine in human plasma. The procedure involved liquid-liquid extraction using toluene, followed by liquid chromatography coupled to UV detection at 292nm. The chromatographic separation of the (+)-(S)- and (-)-(R)-enantiomers of mirtazapine was achieved on a Chiralpak AD column (250 mm x 4.6 mm, 10 mum particle size) protected with a CN guard column, using hexane-ethanol (98:2, v/v) plus 0.1% diethylamine as the isocratic mobile phase, at a flow rate of 1.2ml/min. The total analysis time was less than 12 min per sample. The recoveries of (+)-(S)- and (-)-(R)-mirtazapine were in the 88-111% range with a linear response over the 6.25-625 ng/ml concentration range for both enantionters. The quantification limit (LOQ) was 5 ng/ml. Within-day and between-day assay precision and accuracy were studied at three concentration levels (10, 50 and 250 ng/ml). For both mirtazapine enantiomers, the coefficients of variation (CV) and deviation from the theoretical value were lower than 15% at all concentration levels. The method proved to be suitable for pharmacokinetic studies. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:351 / 356
页数:6
相关论文
共 19 条
[1]   Pharmacokinetics and biotransformation of mirtazapine in human volunteers [J].
Delbressine, LPC ;
Moonen, MEG ;
Kaspersen, FM ;
Wagenaars, GN ;
Jacobs, PL ;
Timmer, CJ ;
Paanakker, JE ;
van Hal, HJM ;
Voortman, G .
CLINICAL DRUG INVESTIGATION, 1998, 15 (01) :45-55
[2]   Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography [J].
Dodd, S ;
Burrows, GD ;
Norman, TR .
JOURNAL OF CHROMATOGRAPHY B, 2000, 748 (02) :439-443
[3]   In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes [J].
Dodd, S ;
Boulton, DW ;
Burrows, GD ;
DeVane, CL ;
Norman, TR .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 (07) :541-544
[4]   Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression [J].
Fawcett, J ;
Barkin, RL .
JOURNAL OF AFFECTIVE DISORDERS, 1998, 51 (03) :267-285
[5]  
Gorman JM, 1999, J CLIN PSYCHIAT, V60, P9
[6]   Determination of mirtazapine in tablets by UV spectrophotometric and derivative spectrophotometric methods [J].
Karasen, N ;
Altinöz, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 24 (01) :11-17
[7]   Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets [J].
Labat, L ;
Dallet, P ;
Kummer, E ;
Dubost, JP .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (02) :365-371
[8]   High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma [J].
Maris, FA ;
Dingler, E ;
Niehues, S .
JOURNAL OF CHROMATOGRAPHY B, 1999, 721 (02) :309-316
[9]   Neurochemical effects of the enantiomers of mirtazapine in normal rats [J].
McGrath, C ;
Burrows, GD ;
Norman, TR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) :121-126
[10]   Biotransformation of mirtazapine by Cunninghamella elegans [J].
Moody, JD ;
Freeman, JP ;
Fu, PP ;
Cerniglia, CE .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1274-1279